Antibodies in diagnosis and therapy. The magic bullet--nearing the century mark
- PMID: 2103498
Antibodies in diagnosis and therapy. The magic bullet--nearing the century mark
Abstract
A truly successful magic bullet therapy for cancer requires the production of agents which can easily reach, accurately recognize and permanently nullify every cancer cell in the body. Moreover, these precise functions must be achieved without adversely affecting normal vital tissues. This demanding approach is examined from the standpoint of animal model systems which satisfy these criteria to various extents. The salient features which contribute to success in these models are presented to provide a basis for evaluating the performance of currently available agents, and to assist in the design of new, more highly perfected 'bullets'. Pertinent issues regarding the therapeutic impact of cellular receptors, internalization pathways, mechanisms of toxin action, kinetics of cell killing, solid tumor penetration, pharmacokinetics and relative potency on target versus non-target cells are all considered. Current strategies using advanced biotechnical approaches to construct more effective targeted agents are addressed in this context.
Similar articles
-
Targeted cancer therapy: conferring specificity to cytotoxic drugs.Acc Chem Res. 2008 Jan;41(1):98-107. doi: 10.1021/ar700108g. Epub 2007 Aug 18. Acc Chem Res. 2008. PMID: 17705444 Review.
-
Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.Anticancer Res. 1996 Mar-Apr;16(2):661-74. Anticancer Res. 1996. PMID: 8687112 Review.
-
Immunotoxins and cytokine toxin fusion proteins.Semin Immunol. 1990 Nov;2(6):467-79. Semin Immunol. 1990. PMID: 2104283 Review.
-
Antibodies and gene therapy: teaching old 'magic bullets' new tricks.Trends Immunol. 2004 Feb;25(2):85-91. doi: 10.1016/j.it.2003.12.001. Trends Immunol. 2004. PMID: 15102367 Review.
-
Effective tumor targeting: strategies for the delivery of Armed Antibodies.Curr Opin Drug Discov Devel. 2005 Mar;8(2):177-83. Curr Opin Drug Discov Devel. 2005. PMID: 15782542 Review.
Cited by
-
Reactive Oxygen Species-Mediated Mechanisms of Action of Targeted Cancer Therapy.Oxid Med Cell Longev. 2017;2017:1485283. doi: 10.1155/2017/1485283. Epub 2017 Jun 18. Oxid Med Cell Longev. 2017. PMID: 28698765 Free PMC article. Review.
-
Optimization and Validation of the Cationization Method for the Fab' Fragment of Antibody Rituximab.ACS Omega. 2025 Mar 26;10(13):12880-12890. doi: 10.1021/acsomega.4c07727. eCollection 2025 Apr 8. ACS Omega. 2025. PMID: 40224423 Free PMC article.
-
Preclinical studies of targeted alpha therapy for breast cancer using 213Bi-labelled-plasminogen activator inhibitor type 2.Br J Cancer. 2003 Mar 24;88(6):944-50. doi: 10.1038/sj.bjc.6600838. Br J Cancer. 2003. PMID: 12644835 Free PMC article.
-
Phage Display Technology as a Powerful Platform for Antibody Drug Discovery.Viruses. 2021 Jan 25;13(2):178. doi: 10.3390/v13020178. Viruses. 2021. PMID: 33504115 Free PMC article. Review.
-
The Role of ROS as a Double-Edged Sword in (In)Fertility: The Impact of Cancer Treatment.Cancers (Basel). 2022 Mar 21;14(6):1585. doi: 10.3390/cancers14061585. Cancers (Basel). 2022. PMID: 35326736 Free PMC article. Review.